Research programme: selective estrogen receptor-beta agonists - Karo Pharma

Drug Profile

Research programme: selective estrogen receptor-beta agonists - Karo Pharma

Alternative Names: KB093823; KB095285; KB095508; KB099520; KB285; KB9520; KB9580

Latest Information Update: 25 Oct 2016

Price : $50

At a glance

  • Originator Karo Bio
  • Class
  • Mechanism of Action Selective estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Preclinical Cancer; Genitourinary disorders; Mesothelioma; Multiple sclerosis
  • Discontinued Major depressive disorder

Most Recent Events

  • 24 Oct 2016 Oasmia Pharmaceutical enters into a collaboration with Karo Pharma to acquire its cancer project, KB 9520
  • 29 Oct 2014 Research programme: selective estrogen receptor-beta agonists - Karo Bio is available for licensing as of 29 Oct 2014.
  • 17 Mar 2014 Karo Bio receives grant from Vinnova for development of an Estrogen receptor-beta agonist in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top